To address limitations of other approaches to kinase drug discovery, Kinagen established the Kinagen Platform to enable a new class of kinase-targeted drugs selective for the unactivated conformation of targeted kinases

The Kinagen Platform combines highly efficient computationally-assisted, scaffold-based rational drug design with a unique physiologic screening approach. The Platform leverages chemical biology advances to identify and rapidly characterize differentiated drug candidates with unique mechanisms of action, driving efficacy, selectivity and safety advantages. As Kinagen’s proprietary scaffold-based chemistries directly target conserved elements of kinases, the Company can pursue applications across a range of therapeutic areas.

Kinagen has established a strong intellectual property position for chemistries that target unactivated kinase conformations, and methods of treatment for a wide range of diseases.